HOME >> BIOLOGY >> NEWS
Impressive new Impact Factors for BioMed Central's open-access journals

Eleven journals published by BioMed Central, the open access publisher, received their first Impact Factor this month. With nine journals in the top 10 of their 2005 Journal Citation Report* category, and ten journals with a 2005 Impact Factor exceeding 3.00, open access journals are confirmed as publishing high-quality, highly cited research.

Genome Biology, BioMed Central's flagship title covering biology in the post-genomic era, has been assessed as having an Impact Factor of 9.71. The journal's first Impact Factor places it in the top five of research journals in the highly competitive Genetics and Heredity field, and the 4th most cited journal in the Biotechnology & Applied Microbiology. Matthew Cockerill, BioMed Central's Publisher, comments, "Genome Biology's impressive Impact Factor is evidence of BioMed Central's commitment to quality, and shows that top researchers at the cutting edge of biology are increasingly choosing open access publication for their best work."

Malaria Journal, with a first Impact Factor of 2.14, is the number two journal in the Tropical Medicine field, and number five in the Parasitology category. Launched in 2001, Malaria Journal was one of the first journals started as part of BioMed Central's independent journal program, and is the first of these independent journals to receive an Impact Factor.

Seven journals in the BMC series also received their first Impact Factors this year. BMC Developmental Biology, with an Impact Factor of 5.41, is ranked at number six in the developmental biology field. BMC Structural Biology enters the Biophysics category at number eight, with an Impact Factor of 5.00. BMC Evolutionary Biology's Impact Factor of 4.45 is the 6th most highly cited journal in the evolutionary biology category. BMC Biotechnology now has an Impact Factor of 3.05, BMC Neuroscience 2.73, BMC Microbiology 2.18, BMC Gastroenterology 1.46.

Dr Cockerill continues, "These impressive rankings demonstrat
'"/>

Contact: Grace Baynes
press@biomedcentral.com
44-207-631-9988
BioMed Central
20-Jun-2006


Page: 1 2

Related biology news :

1. Impact of forest certification in developing countries examined
2. Genome Biologys first Impact Factor 9.71
3. Factors affecting kernel yield in maize
4. BioMed Central announces new interdisciplinary Biofuels Journal
5. BioMed Central announces winners of first open access research awards
6. BioMed Central launches BMC Systems Biology, a new open access journal
7. BioMed Central launches Biology Direct
8. BioMed Central applauds Wellcomes leadership on Open Access
9. BioMed Central welcomes the new National Institutes of Health public access policy
10. BioMed Central announces publishing partnership with The Scientist magazine
11. Public Library of Science announces PLoS ONE: A new approach to open-access publishing

Post Your Comments:
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: